Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AMLX
日付受信時刻ニュースソース見出しコード企業名
2024/12/3021 : 50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/12/0421 : 30Business WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/2723 : 00Business WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/0722 : 22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/0721 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/0721 : 00Business WireAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/0709 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/11/0423 : 00Business WireAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/1722 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/1722 : 00Business WireAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/1522 : 00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/0404 : 06PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/0307 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/0307 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/10/0307 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/09/2606 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/09/1706 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/09/1005 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/2821 : 30Business WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/2707 : 49Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/1222 : 00Business WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/0820 : 14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/0820 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/0820 : 00Business WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/0522 : 00Business WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/08/0222 : 00Business WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/07/1908 : 00PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/07/1020 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/07/1020 : 00Business WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
2024/07/1005 : 01Business WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

最近閲覧した銘柄

Delayed Upgrade Clock